Navigation Links
CorVel Announces Second Quarter Revenues and Earnings
Date:11/4/2008

$0.75

Weighted Shares

Basic 13,927,000 13,790,000

Diluted 14,111,000 14,003,000

CorVel Corporation

Quarterly Results - Condensed Balance Sheet (Unaudited)

March 31, 2008 and September 30, 2008

March 31, 2008 September 30, 2008

Cash 17,911,000 23,600,000

Accounts receivable, net 39,164,000 40,950,000

Prepaid expenses and taxes 5,242,000 5,648,000

Deferred income taxes 4,076,000 3,996,000

Property, net 30,569,000 30,209,000

Goodwill and other assets 43,613,000 45,163,000

Total 140,575,000 149,566,000

Accounts and taxes payable 20,475,000 18,797,000

Accrued liabilities 16,473,000 19,030,000

Deferred tax liability 7,249,000 7,245,000

Paid in capital 80,222,000 83,016,000

Treasury stock -162,302,000 -167,511,000

Retained earnings 178,458,000 188,989,000

Total 140,575,000 149,566,000


'/>"/>
SOURCE CorVel Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. CorVel Announces Expanded Share Buyback
2. CorVel Announces Record Earnings
3. CorVel Announces Appearance at Bank of America Health Care Conference
4. CorVel to Present at UBS Global Healthcare Services Conference
5. CorVel Announces Record Earnings Per Share
6. CorVel Corporation Announces Resumption of Stock Repurchases
7. Psychemedics Corporation Announces Third Quarter Results
8. HealthFitness Announces 2008 Third Quarter Results
9. ATS Medical Announces Third Quarter Results
10. STERIS Corporation Announces Webcast of Analyst Conference
11. Barr Announces Approval of Generic Camptosar(R) Injection, 20 mg/mL
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 1Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 2Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 3Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 4Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 5Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 1Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 2Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 3Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 4